After finishing at $3.30 in the prior trading day, Emergent Biosolutions Inc (NYSE: EBS) closed at $3.20, down -3.03%. In other words, the price has decreased by -$0.1000 from its previous closing price. On the day, 4591818 shares were traded.
Ratios:
Our goal is to gain a better understanding of EBS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 1.07. In the meantime, Its Debt-to-Equity ratio is 1.26 whereas as Long-Term Debt/Eq ratio is at 0.66.
The Benchmark Company Upgraded its Hold to Buy on April 10, 2023, while the target price for the stock was maintained at $22.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 02 when Zoon Kathryn C sold 1,830 shares for $8.35 per share. The transaction valued at 15,280 led to the insider holds 49,971 shares of the business.
Zoon Kathryn C sold 1,700 shares of EBS for $14,246 on May 25. The Director now owns 51,801 shares after completing the transaction at $8.38 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 166.03M and an Enterprise Value of 940.03M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.15 while its Price-to-Book (P/B) ratio in mrq is 0.24. Its current Enterprise Value per Revenue stands at 0.87 whereas that against EBITDA is -1.77.
Stock Price History:
The Beta on a monthly basis for EBS is 1.21, which has changed by -72.06% over the last 52 weeks, in comparison to a change of 27.55% over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $13.67, while it has fallen to a 52-week low of $1.42. The 50-Day Moving Average of the stock is 2.0834, while the 200-Day Moving Average is calculated to be 4.3717.
Shares Statistics:
The stock has traded on average 2.87M shares per day over the past 3-months and 10.57M shares per day over the last 10 days, according to various share statistics. A total of 50.10M shares are outstanding, with a floating share count of 49.75M. Insiders hold about 4.12% of the company’s shares, while institutions hold 79.36% stake in the company. Shares short for EBS as of Feb 15, 2024 were 11.54M with a Short Ratio of 4.02, compared to 11.82M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 22.23% and a Short% of Float of 36.82%.
Earnings Estimates
Its stock is currently analyzed by 3 different market analysts. On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of $0.07 and a low estimate of -$0.33, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.03 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$4.67 and -$5.07 for the fiscal current year, implying an average EPS of -$4.87. EPS for the following year is $1.54, with 2 analysts recommending between $2.51 and $0.57.
Revenue Estimates
3 analysts predict $293.53M in revenue for the current quarter. It ranges from a high estimate of $332.6M to a low estimate of $248M. As of the current estimate, Emergent Biosolutions Inc’s year-ago sales were $330.7M, an estimated decrease of -11.20% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $1.11B, while the lowest revenue estimate was $1.02B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $1.12B, down -4.80% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $1.18B in the next fiscal year. The high estimate is $1.19B and the low estimate is $1.17B. The average revenue growth estimate for next year is up 11.00% from the average revenue estimate for this year.
